[HTML][HTML] Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors

R He, G Sandford, GS Hayward, WH Burns, GH Posner… - Virology Journal, 2011 - Springer
R He, G Sandford, GS Hayward, WH Burns, GH Posner, M Forman, R Arav-Boger
Virology Journal, 2011Springer
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase
(POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-
throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal
expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved
a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of
inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque …
Abstract
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.
Springer